| Document |
Document Title |
|
JP2005535611A |
The present invention provides novel derivatives comprising compounds in the androstane and androstene series, coupled with ascorbic acid, including salts thereof, and represented by one or more of the general formulae: wherein R1, R2, R...
|
|
JP3717511B2 |
Saponin/antigen conjugates and the use thereof for enhancing immune responses in individuals are disclosed. The saponins may be substantially pure or mixtures of saponins.
|
|
JP3710470B2 |
Method, compositions, and compounds for modulating brain excitability to alleviate stress, anxiety, insomnia and seizure activity using certain steroid derivatives that act at a newly identified site on the gamma-aminobutyric acid recept...
|
|
JP2005528353A |
A method for the treatment of diabetes mellitus and conditions associated with diabetes mellitus in an animal comprises administering a non-toxic and therapeutically effective amount of one or more of the following compounds: formula (I,...
|
|
JP2005527496A |
According to one aspect of the invention, there is provided a pharmaceutical formulation for administration by inhalation comprising a compound of formula (I), or a solvate thereof, together with a long-acting ² 2 -adrenoreceptor agonis...
|
|
JP2005522442A |
A compound of formula (I) in the form of a substantially amorphous solid, and processes for the production thereof.
|
|
JP2005519925A |
A pharmaceutical aerosol formulation comprising (i) a compound of formula (I) or a solvate thereof as medicament, (ii) a liquified hydrofluoroalkane (HFA) gas as propellant; and characterised in that the compound of formula (I) or a solv...
|
|
JP2005513024A |
The present invention relates to a method for the treatment of a patient suffering from major depressive disorder by administering to the patient an effective amount of a glucocorticoid receptor antagonist and to methods for establishing...
|
|
JP2005500290A |
There are provided compounds of formula (I) wherein R1 represents C1-6 alkyl or C1-6 haloalkyl; R2 represents a 4-7 membered non-aromatic ring containing 1-3 heteroatoms selected from O, N and S optionally substituted with one or more me...
|
|
JP2004537506A |
The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy...
|
|
JP3587934B2 |
|
|
JP3588369B2 |
A lactone compound, useful as an osteogenetic accelerator, having the formula (I): wherein n is zero or 1 and m is zero or 1, provided that both n and m are not zero at the same time, or a stereoisomer thereof at the 23- and/or 25-positi...
|
|
JP2004531560A |
22,29-epoxy-3,4,6,7,29-pentahydroxy-,(3alpha,4beta,5alpha,6a
lpha,7beta,14beta,22S)-stigmastan-15-one is useful for treating dry eye disorders and other disorders requiring the wetting of the eye.
|
|
JP2004277312A |
To provide a new ligand which enables the simple and rapid detection of a target base sequence in a homogeneous system not needing a B/F separation treatment in an aptamer method for detecting a target base sequence with the bonding affi...
|
|
JP3553989B2 |
|
|
JP3553086B2 |
A pharmaceutical composition contains an extract obtainable from a plant of the genus Trichocaulon or Hoodia containing an appetite suppressant agent having the formula (1). A process for obtaining the extract and a process for synthesiz...
|
|
JP3549125B2 |
Corticoid 17,21-dicarboxylic esters and corticoid 17-carboxylic esters 21-carbonic esters of the formula I with A equal to CHOH and CHClm CH2, C=0, 9(11) double bond; Y equal to H, F, Cl; Z equal to H, F, methyl, R(1) equal to aryl, heta...
|
|
JP3546886B2 |
PCT No. PCT/US94/02397 Sec. 371 Date Aug. 18, 1994 Sec. 102(e) Date Aug. 18, 1994 PCT Filed Mar. 16, 1994 PCT Pub. No. WO94/20520 PCT Pub. Date Sep. 15, 1994Compounds having a broad range of antimicrobial activity generally have a struct...
|
|
JP2004517875A |
This invention uses acetone/water mixtures at various concnetration and temperatures as a cost effective method for recoveing soy saponins of high purity from soybean-derived materials, while also affording an economical means of recover...
|
|
JP3535588B2 |
PURPOSE: To obtain ginsenoside Rh2 useful as raw material for a medicine such as a carcinostatic agent and a perfume by oxidizing a specific terpene with a carbonyl compound, acetylating, reducing, reacting the resultant substance with a...
|
|
JP2004513084A |
The invention relates to 17-Methylene steroids. Method for the production thereof and pharmaceutical compositions containing these compounds. The inventive compounds have an active profile with a hybrid character of such that they act as...
|
|
JP3509812B2 |
To provide an electrochemiluminescence label and an assay using the same. An agent which emits electromagnetic radiation when receiving electrochemical energy is bonded to the object of analysis, and the electrochemical energy is generat...
|
|
JP2004506599A |
This invention relates to methods for treating asthma or allergy in a mammal by administering a 3-aminosteroid compound to a mammal in need thereof. The 3-aminosteroid compound being capable of down regulating the IL-9 pathway and allevi...
|
|
JP2004505990A |
According to one aspect of the invention, there is provided a compound of formula (I) and solvates thereof. There are also provided compositions containing the compound, processes for preparing it, and its use in therapy.
|
|
JP2004504403A |
The present invention relates to a process for the preparation of a compound of formula (I) which comprises the following step: wherein step (a) comprises oxidation of a solution containing the compound of formula (II) wherein the soluti...
|
|
JP3480736B2 |
Mometasone furoate is used in manufacture of a metered dose inhaler formulation for treatment of asthma, disease ofthe upper or lower airway passages, allergic or non-allergic rhinitis and allergic and/or inflammatory diseases of the low...
|
|
JP3476679B2 |
To safely and inexpensively detect the presence of the analyte in a sample with high sensitivity by detecting the electromagnetic radiation emitted from a reagent to which a constant quantity of electrochemical energy is applied. When a ...
|
|
JP3476157B2 |
PURPOSE: To provide the subject new compound having an activity to inhibit absorption of bile acid in the small intestine and useful as a lipid level lowering agent to lower the level of cholesterol and the like by reacting bile acid wit...
|
|
JP2003342291A |
To obtain an estradiol conjugate used as a surrogate compound which makes it possible to conduct microanalysis of an estradiol conjugated by glucuronic acid or sulfuric acid with high accuracy and high reliability, and to provide a metho...
|
|
JP2003313128A |
To obtain a corticosteroid therapeutically effective in treating diseases of the airway passages and lungs such as asthma and also exhibiting low bioavailability and low systemic side-effects when it is administered intranasally or by or...
|
|
JP3441730B2 |
Sex steroid precursors such as dehydroepiandrosterone and dehydroepiandrosterone sulphate, and compounds converted in vivo to either of the foregoing, are utilized for the treatment and/or prevention of vaginal atrophy, hypogonadism, dim...
|
|
JP2003522124A |
Novel phytosterol and/or phytostanol derivatives, including salts thereof, are represented by general formulae: (I), (II), (III), wherein R is a phytosterol or phytostanol moiety, R2 is derived from ascorbic acid and R3 is hydrogen or an...
|
|
JP2003512474A |
The present invention provides methods and compositions to prevent or treat a hematopoietic disorder such as thrombocytopenia or neutropenia by administering to a subject an effective amount of a steroid such as 3,7,16,17-tetrahydroxy-an...
|
|
JP2003511461A |
A conjugated prodrug of an estradiol compound conjugated to a biological activity modifying agent.
|
|
JP3382623B2 |
|
|
JP2003026591A |
To provide a specific anoretic agent, to provide a method for producing the anoretic agent by its synthesis, to provide an appetite suppressant composition containing the anoretic agent, and to provide an anorexiant.A compound represente...
|
|
JP3366639B2 |
PCT No. PCT/CA93/00558 Sec. 371 Date Sep. 5, 1995 Sec. 102(e) Date Sep. 5, 1995 PCT Filed Dec. 21, 1993 PCT Pub. No. WO94/14451 PCT Pub. Date Jul. 7, 1994Steroid compounds of the contignasterol family, including stereoisomers and pharmac...
|
|
JP3359774B2 |
An external preparation for skin comprising at least one member selected from the group consisting of escinol and its salts represented by the following constitutional formula (1): (wherein R<1> is hydrogen atom or hydroxyl group and R<2...
|
|
JP2002543216A |
Steroid derivatives of this invention interact with nuclear liver X receptor (LXR) and ubiquitous receptor (UR) and can be used to treat a variety of LXR- or UR-mediated disorders.
|
|
JP3357427B2 |
17-(3-Furyl) and (4-pyridazinyl)-5 beta ,14 beta -androstane derivatives of formula (I) wherein the symbol @ , the symbol ---, Y, R, R<1>, R<2> and R<3> have the meaning indicated in the specification. Processes of making the said compou...
|
|
JP2002540119A |
The invention provides compositions comprising formula 1 steroids, e.g., 16alpha-bromo-3beta-hydroxy-5alpha-androstan-17-one hemihydrate and one or more excipients, typically wherein the composition comprises less than about 3% water. Th...
|
|
JP3350048B2 |
A method of treatment of androgen-related diseases such as prostate cancer in susceptible male animals, including humans, comprises administering novel antiandrogens and/or novel sex steroid biosynthesis inhibitors as part of a combinati...
|
|
JP3349279B2 |
Novel compounds for use in electrochemiluminescent assays and characterised by containing the structure X - Y - ZwhereinX represents one or more nucleotides which may be the same or different, one or more amino aci...
|
|
JP3343063B2 |
To obtain the subject new derivative useful for a preventive/ therapeutic agent for diseases observed to have hyaluronic acid abnormal decomposition and decomposition accentuation, an inhibitor against hyaluronic acid decomposition, a pr...
|
|
JP2002322168A |
To provide pharmaceutical compounds which reduce undesirable effects occurred at the region where is apart from the target site.Pharmaceutical compounds represented by general formula (I) or their salts or solvates, which are effective i...
|
|
JP2002536415A |
The present invention provides novel methods, pharmaceutical compositions, and articles of manufacture for treating tumors that involve administering an effective amount of digitoxin, or a pharmaceutical salt thereof, wherein the tumor i...
|
|
JP2002533471A |
The invention relates to new 7 alpha , 17 alpha , 17 beta -substituted testosterone derivatives of general formula (I) and their use as pure antiandrogens for the long-term therapy of androgen-dependent diseases, notably for the long-ter...
|
|
JP2002531405A |
Compositions and methods for the treatment of retina and optic nerve head neuropathy are disclosed. The compositions and methods are particularly directed to the use of neurotrophic factor stimulators, such as AIT-082 (neotrofin), in the...
|
|
JP2002249498A |
To provide preparations for intravenous administration, liniments for the skin and membranes, and other skin and membrane care preparations or make-up preparations and fertilizing components, based on new ginesenosides derivatives especi...
|
|
JP2002527448A |
This invention provides 5 alpha -pregnane-3 beta , (20S), 21-triol, 20-O- beta -glucuronide and 5 alpha -pregnane-3 beta ,20R-diol, 20-O- beta -glucuronide and pharmaceutically acceptalbe salts thereof which are useful as progestational ...
|
